Last update 21 Nov 2024

Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Flavin Adenine Dinucleotide Sodium/Sodium Chondroitin Sulfate, MUCOFADIN OPHTHALMIC SOLUTION, ムコファジン点眼液

+ [4]

Target-

Mechanism-

Therapeutic Areas

Eye Diseases

Active Indication

Corneal Diseases

Inactive Indication-

Originator Organization

Wakamoto Pharmaceutical Co., Ltd.

Active Organization

Wakamoto Pharmaceutical Co., Ltd.

ROHTO NITTEN Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (12 Dec 1966),

Corneal Diseases

Regulation-

Structure

Molecular FormulaC27H33N9NaO15P2

InChIKeyNQOZVHXDRLWYCQ-WQLILBPHSA-N

CAS Registry84366-81-4

100 Clinical Results associated with Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

100 Translational Medicine associated with Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

100 Patents (Medical) associated with Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

Literatures (Medical) associated with Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

01 Aug 2021·American Journal of Veterinary ResearchQ3 · AGRICULTURAL & FORESTRY SCIENCE

Effects of an articular cartilage lubrication with a viscosupplement in vitro and in vivo following osteochondral fractures in horses

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Frisbie, David D. ; McIlwraith, C. Wayne ; Raleigh, Aimee R. ; Temple-Wong, Michele M. ; Sah, Robert L.

AbstractOBJECTIVETo assess whether the combination of hyaluronan, sodium chondroitin sul-fate, and N-acetyl-d-glucosamine (HCSG) lubricates articular cartilage in vitro and modulates joint lubrication in vivo.ANIMALS16 healthy adult horses.PROCEDURESThe effects of HCSG injections on SF lubricant properties and joint health, immediately after injury and 2 weeks later, were analyzed by use an equine osteochondral fracture model of post-traumatic osteoarthritis (OA). Middle carpal joints of adult horses were randomly assigned to 1 of 4 surgical treatment groups as follows: normal nonsurgical group (n = 8), normal sham-surgical group (8), OA-induced surgical group with HCSG injection (8), or OA-induced surgical group with saline (0.9% NaCl) solution injection (8). Synovial fluid was aspirated periodically and analyzed for boundary lubrication function and lubricant molecules. At 17 days, joints were screened for gross pathological changes.RESULTSInduction of OA led to an impairment of SF lubrication function and diminished hyaluronan concentration in a time-dependent manner following surgery, with HCSG injection lessening these effects. Certain friction coefficients approached those of unaffected normal equine SF. Induction of OA also caused synovial hemorrhage at 17 days, which was lower in joints treated with HCSG.CONCLUSIONS AND CLINICAL RELEVANCEAfter induction of OA, equine SF lubricant function was impaired. Hyaluronan-sodium chondroitin sulfate–N-acetyl-d-glucosamine injection restored lubricant properties at certain time points and reduced pathological joint changes.

01 Jul 2017·Acta Orthopaedica et Traumatologica TurcicaQ4 · MEDICINE

The comparison of the effects of a novel hydrogel compound and traditional hyaluronate following micro-fracture procedure in a rat full-thickness chondral defect model

Q4 · MEDICINE

ArticleOA

Author: Akman, Yunus Emre ; Talu, Canan Kelten ; Oztas Sukur, Nur Ece ; Senel, Ahmet ; Ozturkmen, Yusuf ; Sukur, Erhan

PURPOSEThe aim of this experimental study was to investigate the impact of HA-CS-NAG compound (hyaluronate, sodium chondroitin sulfate, N-acetyl-d-glucosamine) on the quality of repair tissue after micro-fracture and to compare it with HA (hyaluronat), in a rat full-thickness chondral defect model.METHODSFull-thickness chondral defects were created in a non-weight bearing area by using a handle 2.7-mm drill bit, in the right knees of 33 Sprague-Dawley rats. Each specimen then underwent micro-fracture using a needle. Two weeks after surgery, 3 groups were randomly formed among the rats (n = 33). In Group 1, 0.2 mL of sterile saline solution (0.9%) was injected. In Group 2, 0.2 mL HA with a mean molecular weight of 1.2 Mda was injected. In Group 3, 0.2 mL of HA-CS-NAG compound (hyaluronate, sodium chondroitin sulfate, N-acetyl-d-glucosamine) was injected. The injections were applied on the 14th, the 21st and the 28th postoperative days. All rats were sacrificed on the 42nd postoperative day. Histological analysis of the repair tissue was performed for each specimen by two blinded observers using Wakitani scoring system.RESULTSThere was significantly improved repair tissue in both Group 3 and Group 2 when compared with Group 1. Group 3 showed statistically significant improvement in terms of 'cell morphology' and 'integration of donor with host' when compared to Group 2 (p < 0.001).CONCLUSIONIntra-articular injection of HA-CS-NAG compound after micro-fracture results in significantly improved repair tissue in rats' chondral defects when compared to HA regarding the donor integration and cell morphology.

01 Jan 2017·Vestnik oftal'mologii

Effectiveness of epithelialization therapy after surgical treatment of pterygiu

Article

Author: Trishkin, K S ; Gndoyan, I A ; Petraevskiy, A V

Pterygium is widely distributed in regions with hot and dry climate. Frequent relapses of the disease are due to delayed epithelialization of postoperative corneal erosion, associated inflammation and formation of dry areas of the cornea. Effective stimulation of corneal epithelium regeneration in the postoperative period could reduce the frequency of relapses.AIMto compare the effectiveness, safety and tolerability of different keratoprotectors in patients after surgical treatment of pterygium.MATERIAL AND METHODSA total of 60 patients (73 eyes) with pterygium were operated on using classic McReynolds technique. Depending on the keratoprotector used postoperatively (Korneregel, Balarpan, or Stillavit), the patients were divided into three groups of 20 persons. In each group, the clinical picture during the postoperative period was evaluated at days 1, 3, and 7.RESULTSAs to the subjective symptoms relief and stimulation of epithelization, Stillavit capability was comparable to that of Korneregel, but Stillavit was free of the common side effect of Korneregel - blurred vision after instillation. Epithelialization rate under Stillavit therapy was higher than that under Balarpan.CONCLUSIONStillavit can be recommended as the drug of choice for patients after surgical treatment of pterygium. Components of the preparation (0.16% sodium hyaluronate, 0.05% sodium chondroitin sulfate, and 1% dexapanthenolum) act on each of the links in the pathogenesis of recurrent pterygium - slow epithelialization of the cornea, associated inflammation and formation of dry areas of the cornea.

100 Deals associated with Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Corneal Diseases	JP	Wakamoto Pharmaceutical Co., Ltd.	12 Dec 1966

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Flavin Adenine Dinucleotide Sodium/Chondroitin Sulfate Sodium

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation